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Introduction
Hepatic hemangioendothelioma (HHE) is a common
tumor of the liver in infancy (1). Although benign, these
tumors may cause complications such as cardiac failure,
coagulation disorders and, rarely, hypothyroidism (1,2). The
association between HHE and hypothyroidism has first been
reported in 2000 (3) and there have been very few case
reports since then. In HHE, the main pathophysiology 
can be summarized as an increased type 3 iodothyronine
deiodinase activity and catalysis of the conversion of 
thyroxine (T4) to reverse triiodothyronine (T3), and of T3 to
diidothyronine (T2) by this enzyme. Hypothyroidism 
develops when the rate of inactivation of thyroid hormones
surpasses the rate of their production, and this phenomenon
is known as "consumption hypothyroidism" (1,3,4,5). This
hypothyroidism is resistant to thyroid replacement therapy
and is characterized by low free T3 (fT3) and high reverse T3
(rT3) levels despite the high TSH and relatively high free T4
(fT4) levels (5). High doses of Na L-thyroxine (L-T4) are
required to normalize these parameters (3). It is possible to
keep the Na L-T4 dose lower by administering T4 and T3
together during treatment. However, the ideal option is the
resolution of HHE by treatment or spontaneously (5). 
We present a case initially diagnosed as hypothyroidism
in the newborn period, but later as HHE when it was 
found that Na L-T4 treatment in standard doses remained
inadequate to correct the hypothyroid state. 
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A 28-day-old male patient was referred to our clinic with
a diagnosis of congenital hypothyroidism. The patient was
the product of the 3rd pregnancy of a 36-year-old healthy
mother. Birth weight was 3600 g. Based on a TSH value of
77 mIU/mL (N= 0.5-6.5) reported by the newborn screening
program when the baby was 21 days old, a diagnosis of
congenital hypothyroidism  was made and  Na L-T4 was
started in a dose of 11 μg/kg/day. The patient was referred
to our clinic for follow-up. 
There was no exposure to iodine or any noteworthy
health problem in the family history. The patient’s weight
was 4500 g, length 52 cm, and head circumference 37 cm.
Physical examination revealed mild abdominal distention,
prominent superficial veins on the abdominal skin, and an
enlarged liver palpable 5 cm below the right costal margin.
The thyroid gland was not palpable. The infant had received
a standard daily dose of Na L-T4 for a week. Blood hormone
levels were: TSH >150 mIU/mL, T4 10.8 μg/dL (5.9-16.3),
fT4 2.41 ng/dL (0.9-2.1), T3 0.43 ng/mL (0.94-2.69), and fT3
1.55 pg/mL (2-6.5). Complete blood count and liver function
test results were normal. The mother's thyroid function
tests were normal and no thyroid autoantibodies were
found in the mother or in the baby. Thyroid ultrasonography
was normal. The Na L-T4 dose was increased to 15 μg/kg
daily. Abdominal ultrasonography showed multiple 
hypoechoic lesions with vascularization in both lobes of the
liver, the largest being 2 cm in size. Abdominal magnetic
resonance imaging (MRI) showed multiple hepatic nodules
with decreased signal intensity on T1-weighted images and
increased signal intensity on T2-weighted images, i.e. 
findings consistent with a diagnosis of HHE; the largest
nodule was 3 cm in size (Figure 1). The alpha-fetoprotein
level was high (2667 ng/mL), while the urine vanillylmandelic
acid level was within normal limits. Congestive heart 
failure developed during clinical follow-up and treatment
with digoxin and furosemide was started. A contrast
echocardiographic investigation showed a pulmonary 
arteriovenous fistula. The hemangioendothelioma was
treated with methylprednisolone in doses of 2 mg/kg/day
and alpha-interferon in doses of 3 million U/m2/3 times per
week. The patient's thyroid function disorder was thought
to be due to the activity of the type 3 iodothyronine 
deiodinase expressed by the HHE, but rT3 level could not
be measured due to technical inadequacies. The thyroid
treatment was changed to Bitiron® tablets, which contain
T4 and T3 together (50 μg of Na L-T4 and 12.5 μg of 
triiodothyronine sodium). The cardiac failure resolved on the
12th day of treatment. At the end of one month, blood 
hormone levels were: TSH 4.28 mIU/mL, T4 17.4 μg/dL, fT4
1.85 ng/dL, T3 2.14 ng/mL, and fT3 3.96 pg/mL. Repeat
ultrasonographic examinations showed that the 
hemangioendotheliomas shrank in size, while repeat 
contrast echocardiographic investigations revealed that the
pulmonary arteriovenous fistula had disappeared. The
patient was given methylprednisolone for 3 months.
Abdominal ultrasonography on the 11th month of alpha-
interferon treatment showed multiple nodular lesions with
hypoechoic-heterogenous structures and ill-defined borders
in the liver. The serum alpha-fetoprotein level had
decreased to 5.05 ng/mL. At this time, blood hormone 
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Table 1. The follow-up clinical and laboratory findings and treatment schedule of the patient 
Age Weight Length Thyroid Function Tests Treatment
(g) (cm) TSH fT4 fT3 L-T4 L-T3 PSL α-IFN (U/m2 3 
(mIU/mL) (ng/dL) (pg/mL) (μg/kg/day) (μg/kg/day) (mg/kg/day) times per week)
28 days 4500 52 >150 2.41 1.55 11 - - -
38 days  4500 53.5 >150 2.33 1.85 15 - - -
2.5 mo 4500 57 16.2 1.05 <0.7 18 - - -
3 mo 4500 58 15.9 1.81 1.97 22 - 2 3 million
6 mo 6000 64 2.9 1.85 3.96 8.3 2 ended 3 million
9 mo 7800 68 <0.01 1.5 13.03 3.2 0.8 - 3 million
12 mo 9900 73 0.34 1.38 8.3 1.8 0.46 - 3 million
15 mo 10000 73 1.63 1.23 6.4 ended ended - ended
18 mo 11000 80 1.86 1.22 8.11 - - - -
21 mo 11800 82 0.86 1.22 4.34 - - - -
mo: months;  L-T4: L-thyroxine; L-T3: L-Triiodothyronine; PSL: Prednisolone; α-IFN: α-interferon
Reference ranges: TSH 0.5-6.5 mIU/ml, fT4 0.9-2.1 ng/dL, fT3 2-6.5 pg/mLlevels were: TSH 2.5 mIU/mL, T4 9.54 μg/dL, fT4 1.23
ng/dL, T3 1.75 ng/mL, and fT3 6.46 pg/ml. Thyroid hormone
replacement therapy (Na L-T4 0.6 μg/kg/day + Liothyronine
0.15 μg/kg/day) was discontinued. Blood hormone levels
were completely normal 2 months later (TSH 1.86 mIU/mL,
T4 11.2 μg/dL, fT4 1.22 ng/dL, T3 3.23 ng/mL, fT3 8.11
pg/mL). No recurrence was found at the follow-up 6 months
after treatment discontinuation. The patient was last seen
at age 21 months. Growth and neurological development
were normal and he showed no signs of thyroid deficiency.
Table 1 summarizes the clinical and laboratory findings of
the patient. 
D Di is sc cu us ss si io on n
Huang et al (3) were the first to describe an association
between severe hypothyroidism requiring high-dose thyroxine
support and HHE in an infant. These authors reported that
in the HHE tissue, type 3 iodothyronine deiodinase enzyme
activity was 7.5 times that of the placenta, while Bessho et
al (5) found this level to be more than 10 times that of the
placental tissue. The etiology of the increased type 3
iodothyronine deiodinase activity in HHE is not fully known
(5). Some immunohistochemical markers, such as the 
specific HHE marker antiglucose transporter-1 (GLUT1),
have been reported to be present in infantile hemangioma
and in placental endothelial cells. It has been postulated
that HHE may originate from placental angioblasts (6,7). Mo
et al (8) stated that hemangiomas may arise from embolization
of placental endothelial cells and that the liver carries great
risk regarding hemangioma development as it is the first
organ to be perfused with the incoming blood from the 
placenta.  These postulated mechanisms may explain the
high activity of type 3 iodothyronine deiodinase in HHE and
the  self-limiting growth of the tumor (5). 
Ayling et al (9) have speculated that HHE may 
secrete TSH-like factors that can interact with TSH 
receptors and may be responsible for the thyroid dysfunction.
One patient's postmortem liver tissue was stained
immunohistochemically with TSH and showed positivity 
for the TSH beta subunit together with empty follicles that
supported increased TSH secretion in the thyroid tissue. Ho
et al (10) have similarly reported resistant elevated TSH 
levels despite normal fT3 and fT4 levels in hepatic 
hemangioma patients and stated that the tumor tissue may
produce a TSH-like factor. The absence of clinical signs of
hyperthyroidism in the patient and normal or slightly
increased T3 and T4 levels indicate that the TSH-like factor
was probably inactive. Increased type 3 iodothyronine 
deiodinase activity and ectopic TSH-like factor production
may together or separately cause thyroid dysfunction in
hemangioendothelioma patients (1). The marked increases
in serum rT3 concentrations during treatment with L-T4
could be explained by the increase in the activity of type 3
iodothyronine deiodinase (11). Although we did not know
the type 3 iodothyronine deiodinase enzyme activity in our
patient's hemangioendothelioma tissue and we 
were unable to measure the rT3 level due to technical 
inadequacies, we believe that the cause of the severe
hypothyroidism in our patients was the increased type 3
iodothyronine deiodinase enzyme activity. This view was
supported by the fact that change was observed in the 
thyroid function tests, which returned to normal when T3
was added to the T4 treatment the patient was taking. Our
patient did not have symptoms of hyperthyroidism, such as
tachycardia and restlessness, despite the increased Na 
L-T4 dose, and the thyroid function tests started to return
to normal when a T3 preparation was added to the 
treatment. However, the patient had also started to receive
HHE treatment at this stage and the lesions had started to
shrink. Although the addition of a T3 preparation may have
contributed to the recovery of the thyroid functions, we
believe that the real recovery was due to the regressing
HHE. 
Thyroid dysfunction in HHE is generally related to the
severity and distribution of the hepatic hemangiomas (1).
Most cases of hypothyroidism are reported to have 
widespread liver involvement. This may be due to the
increased enzyme activity in the large tumor area or to 
the decreased hepatic inactivation of deiodinase 
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Figure 1. Abdominal MRI showing multiple hepatic nodulesactivity with the invasion of the liver parenchyma by the
hemangioendothelioma (12). Consistent with this view, we
believe that our case developed severe hypothyroidism due
to the widespread HHE.
Hypothyroidism due to HHE may not be detected on
newborn screening as the lesions usually appear around the
4th to 6th weeks of life. However, HHE cases, which were
symptomatic in the neonatal period, have been reported
(13). Severe symptoms of hypothyroidism may be masked
by HHE complications (3,12). In our patient, the hypothyroid
state was detected with the newborn screening program
and HHE was found on presentation to the endocrinology
clinic for the follow-up of the hypothyroidism. It is well
known that thyroid hormones are necessary for growth 
and development during early infancy and that the early
detection and treatment of hypothyroidism is important to
prevent growth retardation and intellectual loss (5,10,12).
The normal motor and mental development noted in 
our patient may be explained with the early diagnosis and
treatment of the hypothyroidism.
A thyroxine dose of 5-10 μg/kg/day is generally 
adequate for treating congenital hypothyroidism, while very
high doses of T4 and T3, such as 22-70 μg/kg/day, are 
necessary to normalize the serum TSH concentration in 
children with consumption hypothyroidism and these doses
may have to be administered intravenously at times (4,5).
Huang et al (3) have reported that a thyroid hormone dose
up to 8-9 times that accepted for replacement in congenital
hypothyroidism due to thyroid agenesis is required in such
cases. The high replacement dose required and the
increased rT3 level are thought to reflect tumor size 
and type 3 deiodinase activity (4). In addition to the 
hormone replacement treatment, the spontaneous or 
treatment-related regression of HHE is also important in the
normalization of thyroid hormone levels (5). In our patient,
the L-T4 dose had to be increased to as high as 22
μg/kg/day.  From the 15th month on, with regression of the
HHE following the steroid and alpha-interferon treatment,
the patient had no need for any treatment. 
Although spontaneous recovery may be seen in some
HHE cases, the development of serious complications 
may require treatment such as steroids, alpha-interferon,
hepatic artery ligation, radiotherapy, chemotherapy, surgical
resection, and liver transplantation (14). There is no 
consensus on the treatment and management of 
hemangioendotheliomas, but there are practical clinical
algorithms for the evaluation and management of this 
condition  (15,16). Post-treatment recurrences have been
reported although HHE is thought to show self-limiting
growth (5). Long-term follow-up of the patients is therefore
important. The HHE in our case resolved with the 3-month
steroid and 1-year alpha-interferon treatment and there was
no recurrence in the first 6 months following treatment 
discontinuation (Table 1).
Various growth factors that play a role in the proliferative
phase of the hemangioma have been defined. Animal 
studies have shown the type 3 iodothyronine deiodinase
enzyme activity that is stimulated with these growth 
factors to be inhibited by dexamethasone and that the 
consumption effect could therefore be reduced (17).
However, some researchers state that since steroids
increase the conversion of T4 to T3 by disturbing type 1
deiodinase activity and inducing type 3 deiodinase activity,
they may therefore increase the thyroid hormone 
requirement (4). It is difficult to evaluate the effect of the
steroid treatment on thyroid hormone requirement in our
patient, since high-dose thyroid hormone was used 
concomitantly with the steroid treatment.
In conclusion, we believe that HHE should be 
considered and investigated when TSH is high, fT3 low and
rT3 high despite high-dose L-T4 treatment in congenital
hypothyroidism. Our experience with this patient 
has shown that thyroid functions can recover with HHE
treatment and that it is more appropriate to use L-thyroxine
and triiodothyronine (T4+T3 preparation) concomitantly to
achieve euthyroidism during this period.
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